Abstract Background Drug–drug interactions (DDIs) can lead to medication-related harm,
and the older population is at greatest risk. We conducted a systematic review and meta …

Background and Objectives. The drugs most commonly implicated in major potential
interactions are those used in the day‐to‐day clinical management of elderly patients with …

Background The elderly are considered as special population, as they differ from younger
adults in terms of comorbidity, polypharmacy, pharmacokinetics, vulnerability to drug–drug …

Background: Patients with multiple sclerosis (MS) often undergo complex treatment
regimens, resulting in an increased risk of polypharmacy and potential drug-drug …

Purpose Increased numbers of drugs and changes in pharmacokinetic and
pharmacodynamic parameters among elderly people contribute to increased prevalence of …

Background Compared with those without dementia, older patients with dementia admitted
to acute care settings are at higher risk for triad combination of polypharmacy (PP) …

Polypharmacy (PP) is a common problem in modern medicine, especially known to affect
patients with chronic diseases such as multiple sclerosis (MS). With an increasing number of …

The geriatric population is escalating globally, and the need for treating infectious and non-
infectious diseases in elderly patients is also correspondingly increasing worldwide. In …

Poor adherence to prescribed drug treatments is one of the leading causes of illness and
treatment failure, which increases re-hospitalizations. In Mexico, the factors that most …

Objectives To evaluate changes in the use of antipsychotics and medications with
anticholinergic activity (MACs) during hospitalization in older adults with dementia and …